27752357|t|Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
27752357|a|To compare patient-reported outcomes (PROs) in methotrexate (MTX)- naive patients (defined as no prior treatment or ≤3 doses) receiving tofacitinib versus MTX. In the 24- month, phase III, randomised, controlled, ORAL Start trial (NCT01039688), patients were randomised 2:2:1 to receive tofacitinib 5 mg two times per day (n=373), tofacitinib 10 mg two times per day (n=397) or MTX (n=186). PROs assessed included Patient Global Assessment of disease (PtGA), pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and health-related quality of life (Short Form-36 [SF-36]). PROs improved following tofacitinib and MTX treatment: benefits were sustained over 24 months. Patients receiving tofacitinib reported earlier responses which were significantly different between each tofacitinib dose and MTX at month 3 through month 24. At month 6 (primary end point), significant improvements versus MTX were observed in PtGA, pain, HAQ-DI, SF-36 Physical Component Summary (PCS), 5/8 domain scores and FACIT-F with tofacitinib 5 mg two times per day; all PROs, except SF-36 Mental Component Summary Score and Medical Outcomes Survey - Sleep, with tofacitinib 10 mg two times per day. At month 6, the proportion of patients reporting improvements ≥ minimum clinically important difference were significant versus MTX with tofacitinib 5 mg two times per day in PtGA and 3/8 SF-36 domains; and with tofacitinib 10 mg two times per day in PtGA, pain, HAQ-DI, SF-36 PCS, 4/8 domains and FACIT-F. Patients with rheumatoid arthritis receiving tofacitinib 5 and 10 mg two times per day monotherapy versus MTX reported statistically significant and clinically meaningful improvements in multiple PROs over 24 months; onset of benefit with tofacitinib treatment occurred earlier. NCT01039688.
27752357	0	11	Tofacitinib	T103	UMLS:C2930696
27752357	19	31	methotrexate	T103	UMLS:C0025677
27752357	35	55	rheumatoid arthritis	T038	UMLS:C0003873
27752357	57	82	patient-reported outcomes	T170	UMLS:C2987124
27752357	92	102	randomised	T062	UMLS:C0206034
27752357	103	129	phase III ORAL Start trial	T062	UMLS:C0282461
27752357	141	166	patient-reported outcomes	T170	UMLS:C2987124
27752357	168	172	PROs	T170	UMLS:C2987124
27752357	177	189	methotrexate	T103	UMLS:C0025677
27752357	191	194	MTX	T103	UMLS:C0025677
27752357	197	202	naive	T201	UMLS:C0919936
27752357	227	242	prior treatment	T201	UMLS:C1514463
27752357	266	277	tofacitinib	T103	UMLS:C2930696
27752357	285	288	MTX	T103	UMLS:C0025677
27752357	308	317	phase III	T062	UMLS:C0282461
27752357	319	359	randomised, controlled, ORAL Start trial	T062	UMLS:C0206034
27752357	361	372	NCT01039688	T062	UMLS:C0206034
27752357	389	399	randomised	T033	UMLS:C3815594
27752357	417	428	tofacitinib	T103	UMLS:C2930696
27752357	461	472	tofacitinib	T103	UMLS:C2930696
27752357	508	511	MTX	T103	UMLS:C0025677
27752357	521	525	PROs	T170	UMLS:C2987124
27752357	544	580	Patient Global Assessment of disease	T170	UMLS:C4054228
27752357	582	586	PtGA	T170	UMLS:C4054228
27752357	589	593	pain	T033	UMLS:C0030193
27752357	595	643	Health Assessment Questionnaire-Disability Index	T170	UMLS:C3826998
27752357	645	651	HAQ-DI	T170	UMLS:C3826998
27752357	654	710	Functional Assessment of Chronic Illness Therapy-Fatigue	T170	UMLS:C3272505
27752357	712	719	FACIT-F	T170	UMLS:C3272505
27752357	757	770	Short Form-36	T170	UMLS:C3640521
27752357	772	777	SF-36	T170	UMLS:C3640521
27752357	781	785	PROs	T170	UMLS:C2987124
27752357	786	794	improved	T033	UMLS:C0184511
27752357	805	816	tofacitinib	T103	UMLS:C2930696
27752357	821	824	MTX	T103	UMLS:C0025677
27752357	895	906	tofacitinib	T103	UMLS:C2930696
27752357	982	993	tofacitinib	T103	UMLS:C2930696
27752357	1003	1006	MTX	T103	UMLS:C0025677
27752357	1100	1103	MTX	T103	UMLS:C0025677
27752357	1121	1125	PtGA	T170	UMLS:C4054228
27752357	1127	1131	pain	T033	UMLS:C0030193
27752357	1133	1139	HAQ-DI	T170	UMLS:C3826998
27752357	1141	1146	SF-36	T170	UMLS:C3640521
27752357	1147	1173	Physical Component Summary	T170	UMLS:C0282574
27752357	1175	1178	PCS	T170	UMLS:C0282574
27752357	1203	1210	FACIT-F	T170	UMLS:C3272505
27752357	1216	1227	tofacitinib	T103	UMLS:C2930696
27752357	1256	1260	PROs	T170	UMLS:C2987124
27752357	1269	1274	SF-36	T170	UMLS:C3640521
27752357	1275	1305	Mental Component Summary Score	T170	UMLS:C0282574
27752357	1336	1341	Sleep	T038	UMLS:C0037313
27752357	1348	1359	tofacitinib	T103	UMLS:C2930696
27752357	1449	1488	minimum clinically important difference	T033	UMLS:C4277733
27752357	1513	1516	MTX	T103	UMLS:C0025677
27752357	1522	1533	tofacitinib	T103	UMLS:C2930696
27752357	1560	1564	PtGA	T170	UMLS:C4054228
27752357	1573	1578	SF-36	T170	UMLS:C3640521
27752357	1579	1586	domains	T170	UMLS:C3541951
27752357	1597	1608	tofacitinib	T103	UMLS:C2930696
27752357	1636	1640	PtGA	T170	UMLS:C4054228
27752357	1642	1646	pain	T033	UMLS:C0030193
27752357	1648	1654	HAQ-DI	T170	UMLS:C3826998
27752357	1656	1661	SF-36	T170	UMLS:C3640521
27752357	1662	1665	PCS	T170	UMLS:C0282574
27752357	1671	1678	domains	T170	UMLS:C3541951
27752357	1683	1690	FACIT-F	T170	UMLS:C3272505
27752357	1706	1726	rheumatoid arthritis	T038	UMLS:C0003873
27752357	1737	1748	tofacitinib	T103	UMLS:C2930696
27752357	1779	1790	monotherapy	T058	UMLS:C0087111
27752357	1798	1801	MTX	T103	UMLS:C0025677
27752357	1888	1892	PROs	T170	UMLS:C2987124
27752357	1931	1942	tofacitinib	T103	UMLS:C2930696
27752357	1971	1982	NCT01039688	T062	UMLS:C0206034